772 results on '"Culine, Stéphane"'
Search Results
202. Systemic chemotherapy in patients with advanced transitional cell carcinoma of the urothelium and impaired renal function
203. Complete clinical and biological response to zoledronic acid in castrate-resistant prostate cancer metastatic to bone
204. Abiraterone Acetate Withdrawal Syndrome: Does It Exist?
205. Gemcitabine or Gemcitabine Plus Oxaliplatin in the First-Line Treatment of Patients With Advanced Transitional Cell Carcinoma of the Urothelium Unfit for Cisplatin-Based Chemotherapy: A Randomized Phase 2 Study of the French Genitourinary Tumor Group (GETUG V01)
206. Re: International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial
207. Prognostic factors in women treated for ovarian yolk sac tumour: A retrospective analysis of 84 cases
208. Kidney Cancer Pathology in the New Context of Targeted Therapy
209. 5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma
210. Targeted therapies in non-muscle-invasive bladder cancer according to the signaling pathways
211. Class III β-Tubulin Expression Predicts Prostate Tumor Aggressiveness and Patient Response to Docetaxel-Based Chemotherapy
212. Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens
213. miR-143 Interferes with ERK5 Signaling, and Abrogates Prostate Cancer Progression in Mice
214. Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract
215. Do Patients With Advanced Urothelial Carcinoma Benefit From Weekly Paclitaxel Chemotherapy? A GETUG Phase II Study
216. Androgen Deprivation Therapy for Node-Positive Prostate Cancer: Adjuvant Does Not Mean Salvage
217. SERUM PRO-MATRIX METALLOPROTEINASE-7 (PRO-MMP-7) AS A PREDICTIVE MARKER FOR EARLY PROGRESSION AFTER NEPHRECTOMY IN RENAL CELL CARCINOMA
218. USING ADJUVANT CHEMO-HORMONO-THERAPY AFTER RADICAL PROSTATECTOMUY FOR LOCALLY ADVANCED PROSTATE CANCER PATIENTS DOES NOT DELAY CONTINENCE RECOVERY AND HAS A LOW IMPACT ON QUALITY OF LIFE: RESULTS OF MORBIDITY EVALUATION IN PRO 05 PHASE II RANDOMIZED TRIAL
219. VEGF EXPRESSION AS BIOMARKER OF SUNITINIB CLINICAL RESPONSE IN METASTATIC RENAL CLEAR CELL CARCINOMA
220. Prognostic Factors in Unknown Primary Cancer
221. Nonseminomatous germ cell tumors: Assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis
222. Treatment with Sunitinib Enabled Complete Resection of Massive Lymphadenopathy not Previously Amenable to Excision in a Patient with Renal Cell Carcinoma
223. A Lower Risk of Dying from Urological Cancer in Down Syndrome: Clue for Cancer Protecting Genes on Chromosome 21
224. Update on the Medical Treatment of Metastatic Renal Cell Carcinoma
225. Corrigendum to: “European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I” [Eur Urol 2008;53:478–96] and to: “European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part II” [Eur Urol 2008;53:497–513]
226. Antiangiogenèse et cancer du rein
227. European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II
228. High Frequency of Intracerebral Hemorrhage in Metastatic Renal Carcinoma Patients with Brain Metastases Treated with Tyrosine Kinase Inhibitors Targeting the Vascular Endothelial Growth Factor Receptor
229. Editorial Comment on: Postchemotherapy Retroperitoneal Lymph Node Dissection in Advanced Germ Cell Cancer Tumors of the Testis
230. Randomized Trial Comparing Bleomycin/Etoposide/Cisplatin With Alternating Cisplatin/Cyclophosphamide/Doxorubicin and Vinblastine/Bleomycin Regimens of Chemotherapy for Patients With Intermediate- and Poor-Risk Metastatic Nonseminomatous Germ Cell Tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP
231. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure
232. New therapies in renal cell carcinoma
233. Chemotherapy for Advanced Transitional Cell Carcinoma of the Urothelium: Cisplatin or Carboplatin?
234. 2006 Monitoring Report: Clinical practice guidelines: the management of patients with carcinoma of unknown primary site
235. Failure of High-Dose Cyclophosphamide and Etoposide Combined with Double-Dose Cisplatin and Bone Marrow Support in Patients with High-Volume Metastatic Nonseminomatous Germ-Cell Tumours: Mature Results of a Randomised Trial
236. Peroxisome Proliferator-Activated Receptor γ Regulates E-Cadherin Expression and Inhibits Growth and Invasion of Prostate Cancer
237. Gemcitabine and cisplatin after radical cystectomy for bladder cancer in an adjuvant setting: feasibility study from the Genito-Urinary Group of the French Federation of Cancer Centers
238. Hepatic metastases from carcinomas of unknown primary site
239. Inter- and intra-individual variability in transdermal fentanyl absorption in cancer pain patients
240. Author reply
241. Reducing the time interval between cycles using standard doses of docetaxel and lenogastrim support
242. Gemcitabine and docetaxel as front‐line chemotherapy in patients with carcinoma of an unknown primary site
243. Chemotherapy for Elderly Patients with Advanced Transitional Cell Carcinoma.
244. Sensitive HPLC-Fluorescence Method for Irinotecan and Four Major Metabolites in Human Plasma and Saliva: Application to Pharmacokinetic Studies
245. Two Cases of Non–Small-Cell Lung Cancer with Rare Complex Mutation of EGFR Exon 18 But Different Response to Targeted Therapy
246. Chimiothérapie des tumeurs germinales du testicule
247. A limited-sampling strategy to estimate individual pharmacokinetic parameters of vinorelbine in elderly patients with advanced metastatic cancer
248. Adjuvant Chemotherapy After Radical Cystectomy for Urothelial Bladder Cancer: Outcome and Prognostic Factors for Survival in a French Multicenter, Contemporary Cohort
249. Multicentre randomised phase II trial of gemcitabine + platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2.
250. Serum Matrix Metalloproteinase‐7 is an independent prognostic biomarker in advanced bladder cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.